(Q48488976)

12 February 2018

title

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. (English)

1 reference

12 February 2018

0 references

S Schimrigk

1

1 reference

12 February 2018

N Brune

2

1 reference

12 February 2018

K Hellwig

3

1 reference

12 February 2018

C Lukas

4

1 reference

12 February 2018

B Bellenberg

5

1 reference

12 February 2018

M Rieks

6

1 reference

12 February 2018

V Hoffmann

7

1 reference

12 February 2018

D Pöhlau

8

1 reference

12 February 2018

H Przuntek

9

1 reference

12 February 2018

publication date

1 June 2006

1 reference

12 February 2018

European Journal of Neurology

published in

1 reference

12 February 2018

volume

13

1 reference

12 February 2018

issue

6

1 reference

12 February 2018

page(s)

604-610

1 reference

12 February 2018

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

1 reference

The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

[Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

The role of T cells in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

Enumeration of IFN-gamma-producing cells by flow cytometry. Comparison with fluorescence microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

Cytokines in multiple sclerosis: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01292.X

10.1111/J.1468-1331.2006.01292.X

21 January 2018

Identifiers

DOI

1 reference

12 February 2018

PubMed ID

16796584

1 reference

12 February 2018